NFKB1 and colorectal carcinoma: Regarding CRC, our results are supported by an in vivo study showing that orlistat, an inhibitor of lipogenic enzymes, can suppress CRC development by reducing inflammation and inhibiting signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappa B (NF-κB) signaling pathways [36].